833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results

BACKGROUND: The phase IIIb ATLAS-2M study demonstrated non-inferiority of long-acting (LA) cabotegravir (CAB) + rilpivirine (RPV) dosed every 8 weeks (Q8W) compared with every 4 weeks (Q4W) for maintenance of virologic suppression. Hepatitis C virus (HCV) co-infection occurs in ~6% of people with HI...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Ronald, Benn, Paul, Thiagarajah, Shanker, Ford, Susan L, Birmingham, Eileen, Upadhyay, Ojesh R, Garside, Louise, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, Spreen, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643858/
http://dx.doi.org/10.1093/ofid/ofab466.1029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643858/
http://dx.doi.org/10.1093/ofid/ofab466.1029

Ejemplares similares